Retinal vasculitis arising in the context of Behçet's disease is a distinct clinical scenario. The systemic nature of Behçet's disease directly determines the therapeutic strategy, and a protocol-guided approach is essential.
This protocol targets patients presenting with retinal vasculitis whose underlying aetiology is Behçet's disease — a systemic inflammatory condition in which ocular involvement can cause severe and sight-threatening retinal damage.
In this setting, management is shaped by the Behçet's disease background. A targeted biological agent is part of the approach considered for these patients. The complete protocol specifies the full range of options, the selection criteria between them, and the evidence-based regimen.
In cases secondary to Behçet's disease, anti-TNF monoclonal antibodies or interferon-alpha are chosen.
DOI: 10.25259/JORP_34_2024
View source ↗